-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Acyclovir
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/59277-89-3.gif)
| Category | Herpes simplex Virus (HSV) |
| CAS | 59277-89-3 |
| Description | Aciclovir is a synthetic nucleoside analogue active against herpesviruses. It is primarily used for the treatment of herpes simplex virus infections, chickenpox and shingles. |
Product Information
| Synonyms | Valaciclovir Impurity B; Valaciclovir hydrochloride EP Impurity B; Valaciclovir hydrochloride hydrate EP Impurity B; Valaciclovir EP Impurity B; 2-Amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one; 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one; 2-Amino-9-(2-hydroxy-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-Amino-9-(2-hydroxy-ethoxymethyl)-3,9-dihydro-purin-6-one; 2-Amino-9-(2-hydroxyethoxymethyl)-3H-purin-6-one; 2-Amino-9-[(2-hydroxyethoxy)methyl]-6,9-dihydro-3H-purin-6-one; 2-Amino-9-[(2-hydroxyethoxy)methyl]-9H-purin-6-ol; 9-(2-Hydroxyethoxymethyl)guanine; Acicloftal; Aciclovir; Acivir; ACV; Acyclo V; Acycloguanosine; Avirase; Axiluowei; Cargosil; Gerpevir; Herpevir; Lovir; Novirus; NSC 645011; Poviral; Rouz-Aciclovir; Vicclox; Vipral; Virax; Virless; Virorax; Virovir; Wellcome 248U; Zirax; Zovirax; Zyclir |
| IUPAC Name | 2-amino-9-(2-hydroxyethoxymethyl)-1H-purin-6-one |
| Molecular Weight | 225.20 |
| Molecular Formula | C8H11N5O3 |
| Canonical SMILES | C1=NC2=C(N1COCCO)NC(=NC2=O)N |
| InChI | InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15) |
| InChIKey | MKUXAQIIEYXACX-UHFFFAOYSA-N |
| Boiling Point | 595 °C at 760 mmHg |
| Melting Point | 256-257 °C |
| Flash Point | 302.4±32.3 °C |
| Purity | >98% |
| Density | 1.771±0.14 g/cm3 |
| Solubility | Soluble in DMSO, DMF |
| Appearance | White Crystalline Powder |
| Storage | Store at 2-8 °C |
| Complexity | 308 |
| Exact Mass | 225.086182 |
| Index Of Refraction | 1.762 |
| In Vitro | Acyclovir reduces cell viability in a dose- and timedependent, blocks DNA synthesis, thereby arresting the cell cycle in G2/M and S phases and increasing the sub-G1 hypodiploid peak in a dose-dependent manner. Acyclovir induces Apoptosis through activates Caspase-3 and presences nuclear DNA fragmentation. |
| In Vivo | Acyclovir (20 mg/kg; p.o.; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production. |
| PSA | 119.05000 |
| Target | HSV, IC50 Value: 0.53-0.75 uM; Apoptosis; Antibiotic; Bacterial |
| Vapor Pressure | 0.0±1.7 mmHg at 25°C |
| XLogP3-AA | -1.9 |